Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer

Peter Black, MD
Published: Wednesday, Aug 09, 2017



Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Since only 20% to 25% of patients have an objective response, developing biomarkers is important to determine which treatments a patient should receive, explains Black. PD-L1 is a current biomarker in development, but currently has no utility in bladder cancer, states Black. Additionally, peripheral immune cells and sequencing T-cell receptors are also in development.
 


Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Since only 20% to 25% of patients have an objective response, developing biomarkers is important to determine which treatments a patient should receive, explains Black. PD-L1 is a current biomarker in development, but currently has no utility in bladder cancer, states Black. Additionally, peripheral immune cells and sequencing T-cell receptors are also in development.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x